Menu
Search
|

Menu

Close
X

MannKind Corp MNKD.OQ (NASDAQ Stock Exchange Global Market)

1.70 USD
-0.08 (-4.49%)
As of Jul 14
chart
Previous Close 1.78
Open 1.73
Volume 348,632
3m Avg Volume 530,195
Today’s High 1.75
Today’s Low 1.67
52 Week High 6.96
52 Week Low 1.09
Shares Outstanding (mil) 104.68
Market Capitalization (mil) 526.55
Forward P/E 3.73
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
3
FY17
12
FY16
175
FY15
0
EPS (USD)
FY18
-0.251
FY17
-1.120
FY16
1.255
FY15
-4.438
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
3.73
32.76
Price to Sales (TTM)
vs sector
2.93
5.73
Price to Book (MRQ)
vs sector
--
5.45
Price to Cash Flow (TTM)
vs sector
3.97
23.29
Total Debt to Equity (MRQ)
vs sector
--
16.72
LT Debt to Equity (MRQ)
vs sector
--
12.39
Return on Investment (TTM)
vs sector
--
14.61
Return on Equity (TTM)
vs sector
--
16.34

EXECUTIVE LEADERSHIP

Kent Kresa
Chairman of the Board, Since 2016
Salary: --
Bonus: --
Michael Castagna
Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Rosabel Alinaya
Acting Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Since 2017
Salary: --
Bonus: --
Steven Binder
Chief Financial Officer, Principal Accounting Officer, Since 2017
Salary: --
Bonus: --
Linda Adreveno
Senior Vice President - Human Resources, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

30930 Russell Ranch Rd Ste 301
WESTLAKE VILLAGE   CA   91362-7378

Phone: +1818.6615000

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.

SPONSORED STORIES